Inflammatory mediators in the ear canal

Inflammatory mediators in the ear canal refer to a diverse group of signaling molecules and biochemical agents that orchestrate the inflammatory response within the external auditory canal and surrounding tissues (Source [2], [6]). These mediators include proinflammatory cytokines such as Tumor necrosis factor alpha (TNF-α), Interleukin-1 beta (IL-1β), and Interleukin-6 (IL-6), as well as chemokines, prostaglandins, and components of the complement system (Source [1], [6], [13]). In conditions like otitis externa or otitis media, these substances are released by resident immune cells and epithelial cells in response to pathogens like Pseudomonas aeruginosa or Staphylococcus aureus (Source [3], [10]). They promote vasodilation, increase vascular permeability, and recruit leukocytes, leading to symptoms of pain, edema, and discharge (Source [2], [10]). Therapeutic intervention typically involves topical corticosteroids (e.g., dexamethasone, hydrocortisone), which suppress the production of these mediators by inhibiting the NF-κB pathway and phospholipase A2 (Source [4], [5]). While effective, these treatments must be used cautiously in cases of tympanic membrane perforation to avoid potential ototoxicity (Source [5], [11]).

Other names

Pro-inflammatory cytokines of the earInflammatory markers of the external auditory canalChemical mediators of otitisOtic inflammatory signaling molecules

Drugs targeting these mediators typically work by inhibiting their synthesis or signaling pathways. Corticosteroids (e.g., dexamethasone) inhibit phospholipase A2 and the NF-kappaB pathway, reducing the production of cytokines and prostaglandins. NSAIDs (e.g., ibuprofen) inhibit cyclooxygenase enzymes to decrease prostaglandin levels. Biologics (e.g., anakinra) directly neutralize specific cytokines like IL-1.